Nexalin Technology, Inc. announced on October 17, 2024, the publication of clinical trial results in Alzheimer’s Research & Therapy, demonstrating improvements in memory and cognitive function for patients with mild Alzheimer’s disease. The study utilized the company's proprietary Deep Intracranial Frequency Stimulation (DIFS) technology.
The trial enrolled 46 patients, with 23 in the DIFS treatment group showing notable improvements in key cognitive markers. Specifically, significant gains were observed in Mini-Mental State Examination (MMSE) scores (p = 0.041) and Montreal Cognitive Assessment (MoCA) scores (p = 0.025). Functional MRI (fMRI) scans also revealed increased local neural activity and blood flow in the hippocampus, a brain region critical for memory processing.
These findings are significant as they validate the potential of non-invasive brain stimulation to transform Alzheimer's treatment by addressing underlying neural decline. The company plans to initiate a robust clinical trial using different waveform frequencies to further enhance clinical response and is exploring potential partnerships to offer this therapy globally.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.